MD430C2 - Способ получения лейкоцитарных интерферонов человека - Google Patents

Способ получения лейкоцитарных интерферонов человека

Info

Publication number
MD430C2
MD430C2 MD95-0076A MD950076A MD430C2 MD 430 C2 MD430 C2 MD 430C2 MD 950076 A MD950076 A MD 950076A MD 430 C2 MD430 C2 MD 430C2
Authority
MD
Moldova
Prior art keywords
pst
pbr
leucocytar
interferone
preparation
Prior art date
Application number
MD95-0076A
Other languages
English (en)
Romanian (ro)
Inventor
Van Norman Goeddel David
Pestka Sidney
Original Assignee
F.Hoffmann-La Roche Ag
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag, Genentech, Inc. filed Critical F.Hoffmann-La Roche Ag
Publication of MD430C2 publication Critical patent/MD430C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к технологии рекомбинации ДНК, т.е. к способам, использующимся в рекомбинантной ДНК-технологии, и к продуктам, полученным этими способами. Штамм бактерий Eschericha coli трансформируют рекомбинантами из группы pLeIF A 25, pLeIF B trp 7, pLeIF C trp 35, pLeIF D trp 11, pLeIF F trpI, pLeIF I trp 1 и pLeIF J trp I, далее культивируют трансформанты, выделяют и очищают лейкоцитарный интерферон.
MD95-0076A 1980-07-01 1994-12-30 Способ получения лейкоцитарных интерферонов человека MD430C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16498680A 1980-07-01 1980-07-01
US18490980A 1980-09-08 1980-09-08
US20557880A 1980-11-10 1980-11-10
US06/256,204 US6610830B1 (en) 1980-07-01 1981-04-21 Microbial production of mature human leukocyte interferons

Publications (1)

Publication Number Publication Date
MD430C2 true MD430C2 (ru) 1996-06-30

Family

ID=27389083

Family Applications (1)

Application Number Title Priority Date Filing Date
MD95-0076A MD430C2 (ru) 1980-07-01 1994-12-30 Способ получения лейкоцитарных интерферонов человека

Country Status (6)

Country Link
US (2) US6610830B1 (ru)
KR (1) KR860001558B1 (ru)
CA (1) CA1341583C (ru)
GE (1) GEP20074163B (ru)
MD (1) MD430C2 (ru)
ZW (1) ZW14781A1 (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835557B1 (en) * 1980-01-08 2004-12-28 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human interferon-like polypeptides
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US7959910B2 (en) * 2000-07-31 2011-06-14 Biolex Therapeutics, Inc. C-terminally truncated interferon alpha variants
CA2427850A1 (en) * 2000-11-03 2002-05-10 Sidney Pestka Interferons, uses and compositions related thereto
FR2822845B1 (fr) * 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
EP1549675B1 (en) * 2002-08-31 2008-02-13 CJ Corp Glycosylated human interferon alpha isoform
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
JP2006506097A (ja) * 2002-11-18 2006-02-23 マキシジェン， インコーポレイテッド インターフェロン−αのポリペプチドおよび結合体
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
DK1667708T5 (da) 2002-12-26 2012-11-12 Mountain View Pharmaceuticals Polyethylenglycolkonjugater af interferon-beta-1b med forøget biologisk styrke in vitro
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
GB2426521A (en) 2004-02-02 2006-11-29 Ambrx Inc Modified human four helical bundle polypeptides and their uses
EP1753779A2 (en) * 2004-05-19 2007-02-21 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
US7619067B2 (en) * 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
CN103030690A (zh) * 2005-06-03 2013-04-10 Ambrx公司 经改良人类干扰素分子和其用途
WO2007127949A2 (en) * 2006-04-27 2007-11-08 Sko Flo Industries, Inc. Flow control valve
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
EP2069399A2 (en) * 2007-04-11 2009-06-17 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
BRPI0814363A2 (pt) * 2007-07-25 2015-01-27 Biolex Therapeutics Inc Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
CA2698396C (en) * 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
CA2729943A1 (en) 2008-07-08 2010-01-14 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
RU2014102102A (ru) 2011-06-23 2015-07-27 Дигна Байотек, С.Л. КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
WO2013175487A2 (en) * 2012-03-30 2013-11-28 Krishnan Archana Rajesh Codon optimized sequence for an antiviral protein
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862495D1 (en) 1977-11-08 1989-05-24 Genentech Inc Plasmid for transforming bacterial host to render it capable of polypeptide expression
US4411994A (en) 1978-06-08 1983-10-25 The President And Fellows Of Harvard College Protein synthesis
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
IN150740B (ru) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
ES479300A1 (es) 1979-04-04 1979-07-01 Cusi Lab Procedimiento de obtencio de &-metil, 4(2'tienil carbonilz) fenil acetato de p-acetamido fenol.
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4418149A (en) 1980-01-10 1983-11-29 President And Fellows Of Harvard College Fused hybrid gene
US4801685A (en) 1981-08-14 1989-01-31 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shigekazu N. et al. Synthensin E. coli of a polypeptide with human leukocyte interferon activity. Nature, v. 284, March, 1980, p. 316-320. *

Also Published As

Publication number Publication date
GEP20074163B (en) 2007-07-10
CA1341583C (en) 2008-11-18
KR830006422A (ko) 1983-09-24
US6482613B1 (en) 2002-11-19
ZW14781A1 (en) 1982-04-21
US6610830B1 (en) 2003-08-26
KR860001558B1 (ko) 1986-10-04

Similar Documents

Publication Publication Date Title
MD430C2 (ru) Способ получения лейкоцитарных интерферонов человека
MD431C2 (ru) Способ получения лейкоцитарного интерферона
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
KR970000808B1 (en) Human proapolipoprotein a-1 expression
MY101972A (en) Primate interleukin - 4
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
DK188582A (da) Bacillus-kloningsvektorer rekombinations-dna-molekyler bacillus-vaerter transformeret dermed samt fremgangsmaader til ekspressionaf fremmede dna-sekvenser og fremstilling af polypeptideer som er kodede dermed
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
ES8702431A1 (es) Procedimiento para preparar una proteina inhibidora de la coagulacion de la sangre
DE3586697D1 (en) Aktive thymopentin-analoga.
DK54184A (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human (interleukin) to-lignende polypeptider
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
FI861653A7 (fi) Eristetty DNA-yhdiste, joka koodaa rekombinantti DNA isopenisilliini N-syntetaasia, sitä sisältävät vektorit ja menetelmä isopenisilliini N-syntetaasiaktiivisuuden tuottamiseksi näiden avulla
JPS615392B2 (ru)
GR3034600T3 (en) Grb3-3 gene, variants and uses thereof
GB9215232D0 (en) Vaccines
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
EP0770137A4 (en) IMPROVEMENTS IN PROTEIN PRODUCTION IN HOST CELLS
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
WO1990003394A3 (fr) Nouvelles lymphokines, sequences d'adn codant pour ces lymphokines et compositions pharmaceutiques contenant ces lymphokines
IT8521507A0 (it) Vettore di clonaggio, molecole di dna ricombinante, ceppi di bacillus subtilis trasformati con dette molecole e metodi per l'espressione di geni eterologhi e produzione e secrezione di proteine codificate da detti geni.